PTO/SB/30 (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ork Reduction Act of 1995, no persons are required to re-

REQUEST **FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL**

Address to: **Commissioner for Patents Box RCE** Washington, DC 20231

spond to a collection of information unless it displays a valid OMB control number	
Application Number	09/487023
Filing Date	January 19, 2000
First Named Inventor	Dr. Parķash Gill
Group Art Unit	1635
Examiner Name	S. McGarry
Attorney Docket No.	VASG-P02-003

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114	
a. Previously submitted	
i. Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on (Any unentered amendment(s) referred to above will be entered).	
ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on	
iii. Other	
b. x Enclosed	
i. x Amendment/Reply	
ii. Affidavit(s)/Declaration(s)	
iii. Information Disclosure Statement (IDS)	
iv. Other	
2. Miscellaneous	
a. Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for	
a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)	
b. Other	
3. Fees The RCE fee under 37 CFR 1.17 (e) is required by 37 CFR 1.114 when the RCE is filed.	
a. x The Director is hereby authorized to charge the following fees, or credit any overpayments, to	
Deposit Account No. 18-1945	
i. X RCE fee required under 37 CFR 1.17(e)	
ii. x Extension of time fee (37 CFR 1.136 and 1.17)	
iii. Other	
b. Check in the amount of \$ enclosed	
c. Payment by credit/ca/d (Form PTO-2038 enclosed)	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
Name (Print/Type) Matthew F. Vincent / Registration No. (Attorney/Agent) 36,709	
Signature Date August 6, 2003	
~ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: 8/6/03 Signature: Joseph Ryan (Joanne Ryan)	
11	

08/11/2003 AWDNDAF4220000089 181945 09487023

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 8/6/03

Signature: Joanne Ryan)

Docket No.: VASG-P02-003

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Plant Application of:

Gill et al

Application No.: 09/487023

Group Art Unit: 1635

Filed: January 19, 2000

Examiner: McGarry, S.

For: METHOD AND COMPOSITION FOR

TREATMENT OF KAPOSI'S SARCOMA

RESPONSE ACCOMPANYING REQUEST FOR CONTINUED EXAMINATION

Mail Stop RCE Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

This paper is filed in response to the outstanding Final Office Action, mailed 6 February 2003 in connection with the above-referenced application. The time period for response has been extended to August 6, 2003 by the accompanying petition for a three-month extension of time. This amendment and response is also accompanied by a Request for Continued Examination. The undersigned hereby authorizes any additional fees which may be due in connection with the present paper to be charged to Deposit Account 18-1945.

9224839_1